Selectivity of Phospholipid Hydrolysis by Phospholipase A₂ Enzymes in Activated Cells Leading to Polyunsaturated Fatty Acid Mobilization

Alma M. Astudillo, María A. Balboa, and Jesús Balsinde¹

Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Valladolid, 47003 Valladolid, Spain, and
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain

¹Corresponding author: Instituto de Biología y Genética Molecular, Calle Sanz y Forés 3, 47003 Valladolid, Spain. Phone: 34-983-423-062; FAX: 34-983-184-800; E-mail: jbalsinde@ibgm.uva.es

Running Title: Selectivity of Phospholipase A₂ Enzymes.

Key Words: phospholipase A₂, lipid mediator, glycerophospholipid, arachidonic acid, docosahexaenoic acid, transacylase, monocyte, macrophage, inflammation, innate immunity.

Abbreviations: AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; PLA₂, phospholipase A₂; sPLA₂, secreted phospholipase A₂; iPLA₂, calcium-independent phospholipase A₂; cPLA₂, cytosolic phospholipase A₂; CoA-IT, CoA-independent transacylase; PC, choline glycerophospholipid; PE, ethanolamine glycerophospholipid; PI, phosphatidylinositol; LPC, choline lysoglycerophospholipid; LPE, ethanolamine lysoglycerophospholipid; PlsEtn, ethanolamine plasmalogen; lysoPLsEtn, ethanolamine lysoplasmalogen; SPM, specialized pro-resolving mediators.

Abstract

Phospholipase A₂s are enzymes that hydrolyze the fatty acid at the *sn*-2 position of the glycerol backbone of membrane glycerophospholipids. Given the asymmetric distribution of fatty acids within phospholipids, where saturated fatty acids tend to be present at the *sn*-1 position, and polyunsaturated fatty acids such as those of the omega-3 and omega-6 series overwhelmingly localize in the *sn*-2 position, the phospholipase A₂ reaction is of utmost importance as a regulatory checkpoint for the mobilization of these fatty acids and the subsequent synthesis of proinflammatory omega-6-derived eicosanoids on one hand, and omega-3-derived specialized pro-resolving mediators on the other. The great variety of phospholipase A₂s, their differential substrate selectivity under a variety of pathophysiological conditions, as well as the different compartmentalization of each enzyme and accessibility to substrate, render this class of enzymes also key to membrane phospholipid remodeling reactions, and the generation of specific lipid mediators not related with canonical metabolites of omega-6 or omega-3 fatty acids. This review highlights novel findings regarding the selective hydrolysis of phospholipids by phospholipase A₂s and the influence this may have on the ability of these enzymes to generate distinct lipid mediators with essential functions in biological processes. This brings a new understanding of the cellular roles of these enzymes depending upon activation conditions.

Introduction

It is well established that the fatty acyl chains of membrane lipids play a wide variety of biological functions including signaling; thus the enzymes regulating phospholipid fatty acid recycling constitute a key step for the fine regulation of lipid mediator production during cell activation.

A prime example of bioactive fatty acid is arachidonic acid (20:4*n*-6, AA), an omega-6 fatty acid that is found at relatively high levels in cells involved in innate immunity reactions, such as monocytes, macrophages and dendritic cells [1-3]. AA is the common precursor of the eicosanoids, a family of lipid mediators with fundamental roles in physiology and pathophysiology, particularly in inflammatory reactions [4-6]. The eicosanoids affect immune regulation by modulating cell activation at different points, including differentiation and migration, phagocytic capacity, and cytokine production [7-10].

Similarly, docosahexaenoic acid (22:6*n*-3, DHA) and related long-chain omega-3 fatty acids eicosapentaenoic acid (20:5*n*-3, EPA) and docosapentaenoic acid (22:5*n*-3, DPA), also found in major inflammatory cells, can be oxygenated to generate biomolecules known as protectins, resolvins, and maresins (collectively called specialized pro-resolving mediators, SPM), which account for much of the biological activity of omega-3 fatty acids, and are involved in the resolution phase of inflammation, clearance of apoptotic cells, tissue repair and regeneration, and anti-nociceptive actions [11]. In addition, omega-3 fatty acids may promote anti-inflammatory reactions by themselves by acting on fatty acid-sensing receptors [12, 13].

Fatty acid-derived mediators are produced during inflammation in two temporal waves with opposite effects, when cells switch the type of mediators produced from pro- to anti-inflammatory [14]. Thus, the immediate production of proinflammatory AA-derived

eicosanoids after the insult is progressively followed by accumulation of anti-inflammatory lipoxins and other pro-resolving lipid mediators derived from omega-3 fatty acids, a process that initiates resolution of inflammation and the return to homeostasis [11, 14]. Thus, cells appear to possess intrinsic mechanisms to dampen inflammation to avoid excessive damage that might lead to irreversible injury.

In addition to the expression of polyunsaturated fatty acid-metabolizing enzymes, availability of the fatty acid in free form is well established to constitute a limiting factor for the biosynthesis of eicosanoids and pro-resolving lipid mediators [1, 15]. Such free fatty acid availability is provided by phospholipase A₂s, the enzymes that cleave the *sn*-2 position of glycerophospholipids [16]. Multiple PLA₂ enzymes co-exist in a single cell, each exhibiting potentially different headgroup and/or fatty acid preferences. Acting frequently in a co-ordinate manner, cellular PLA₂s provide a tight regulation of biological processes involving membrane phospholipid fatty acid rearrangement (**Figure 1**). PLA₂s are found in practically all types of organisms, and in mammals they are ubiquitously expressed throughout most cells and tissues, suggesting their importance in life processes. The variety of functions of PLA₂s in physiology, far from being only circumscribed to activated states of immune cells, have become more evident in the last years with the study of the phenotypes of genetically-manipulated mice [16,17].

More than thirty enzymes with PLA₂ activity have been described and, based on sequence similarities, they are currently classified in 16 groups, each containing several sub-groups [16]. However, based on biochemical features these enzymes are frequently grouped into six major families: secreted phospholipase A₂s (sPLA₂), calcium-independent phospholipase A₂s (iPLA₂), cytosolic phospholipase A₂s (cPLA₂), platelet activating factor acetyl hydrolases (PAF-AH, also known as lipoprotein-associated phospholipase A₂, Lp-PLA₂), lysosomal phospholipase A₂ (L-PLA₂) and the adipose phospholipase A (AdPLA₂)

[16-20]. Extensive *in vitro* kinetic studies have been recently carried out with most of these enzymes. Many of the studies have taken advantage of the analytical power of mass spectrometry-based lipidomics [21-24], which provided valuable information as to the substrate preference of these enzymes. Nevertheless, factors that take part in the microenvironment of the enzymes, such as the complex membrane composition, compartmentalization of the enzyme and the different physiological and pathophysiological scenarios of the cell (including cross-talk between PLA₂ forms), may produce as a result a variety of lipid molecules that orchestrate global responses and cannot be easily reproduced in *in vitro* assays.

In general terms, PLA₂s participate in the Lands cycle of phospholipid fatty acid recycling [1, 15, 25], whereby the fatty acid composition at the *sn*-2 position of phospholipids is tightly controlled by a balance between hydrolytic reactions mediated by PLA₂s *versus* activation of the free fatty acid by acyl-CoA synthetases and subsequent incorporation into phospholipids by lysophospholipid:acyl-CoA acyltransferases. Further remodeling reactions also occur that are catalyzed primarily by CoA-independent transacylase (CoA-IT) [15, 26, 27]. In resting cells the reacylation reactions dominate, but in stimulated cells the dominant reaction is the PLA₂-mediated deacylation step, which results in a dramatic increase in the levels of free fatty acids, notably AA and omega-3 fatty acids, which will now be available for eicosanoid [1, 14, 15, 28, 29] or SPM [30-32] synthesis, depending on the temporal phase of the activation process (**Figure 1**).

While our current knowledge on the mechanisms governing the expression levels of PLA₂s both at gene and protein level is still scarce for the majority of members of this superfamily of enzymes, much information has accumulated on the cellular regulation of their enzymatic activities and *in vitro* substrate preferences. This review is aimed at relating recent findings on the ability of PLA₂s to selectively hydrolyze different phospholipid

substrates in cells with the generation of bioactive lipid mediators. Key current studies are discussed, focusing primarily on cPLA₂ α , iPLA₂-VIA, sPLA₂-V and sPLA₂-X, as these are the PLA₂ forms classically involved in the production of fatty acid-derived mediators [15, 33-36].

Group IVA phospholipase A₂ (cPLA₂ α)

Group IVA PLA₂, also known as cytosolic phospholipase A₂ α (cPLA₂ α) is long known to exhibit marked preference for phospholipid substrates containing AA at the *sn*-2 position. The aromatic residues of cPLA₂ α interact with the double bonds of AA, making the enzyme selective for this fatty acid. cPLA₂ α also displays significant activity towards EPA but, very remarkably, it shows little or no activity towards DHA [21, 24, 37]. This may be related to the fact that, unlike AA or EPA, DHA does not have a double bond at C5; thus the fatty acid does not adjust well within the cPLA₂ α 's active site [16, 24, 37, 38].

cPLA₂ α is widely accepted as the critical enzyme regulating AA mobilization in cells under a wide variety of activation conditions [39-42]. Various cross-talk mechanisms involving cPLA₂ α and sPLA₂ have been described that result in amplified AA mobilization responses [43-50]. A number of recent reviews are available that cover in a comprehensive manner different aspects of cPLA₂ α biochemistry and cell regulation, and the reader is kindly referred to these for specific details [15, 16, 33, 51-53]. In the following we focus on recent studies that have unveiled previously unrecognized cellular roles and modes of regulation of cPLA₂ α activity.

First of all, it should be emphasized that, although cPLA₂ α manifests a marked selectivity for phospholipids that contain AA at the *sn*-2 position, this does not mean in any way that, in cells, the enzyme can not hydrolyze other fatty acyl residues to a significant extent even if this occurs at a lower rate [24]. This points out the importance of cellular

compartmentalization in the regulation of biological activity, i.e. the phospholipid fatty acid composition of the membrane to which the enzyme translocates during cell activation. In this regard, it has been recently shown that cPLA₂ α is not only instrumental in effecting AA mobilization for eicosanoid production during inflammation reactions, but also regulates membrane phospholipid remodeling leading to the formation of phospholipid molecules with defined composition that participate in the execution of other responses such as generation of reactive oxygen species and secretion of bactericidal hydrolases [54]. One of such molecules is an unusual PI species which contains arachidonate at both the *sn*-1 and *sn*-2 positions of glycerol [55, 56]. In addition to its biological roles in innate immune reactions mentioned above [54], this is a short-lived species that may also act as a transient acceptor for the incorporation of arachidonic acid into various cellular phospholipid classes [56]. Owing to its high arachidonic acid content, PI is also a major source for the release of this fatty acid via cPLA₂ α in activated immune cells [55, 57].

In vitro studies suggest that cPLA₂ α does not show clear preference for the headgroup present at the *sn*-3 position, although a slight preference for zwitterionic phospholipids such as PC and PE has recently been pointed out [24]. In this regard, mass spectrometry analyses of glycerophospholipid hydrolysis during macrophage activation by phagocytic stimuli have unveiled links between the hydrolysis of either AA-containing PC or -PE and the formation of specific eicosanoid molecules [57]. During macrophage phagocytosis, the bulk of AA lost from membranes appears to originate from PC and PI, with seemingly little or no contribution from PE [57]. However, use of an inhibitor of CoA-IT that blocks the transfer of AA from PC to PE results in highly significant losses of AA from PE, indicating that during stimulation conditions AA is hydrolyzed from PE and the pools are rapidly replenished with AA from PC via transacylation reactions mediated by CoA-IT. Importantly, under these inhibitory conditions, the production of lipoxygenase

metabolites increases, suggesting that the process of AA transfer between phospholipid classes does regulate the production of specific eicosanoids [57]. This opens the intriguing question of whether the synthesis of different eicosanoids is regulated by the action of cPLA₂ α on different phospholipid pools, and whether the different accessibility of cPLA₂ α to such pools can modify the course of the inflammatory response. In studies on the cPLA₂ α -regulated eicosanoid response of bone marrow-derived mast cells, it was found that maturation of these cells is associated with phospholipid remodeling regulated in part by cPLA₂ α , leading to a general decrease in AA-containing PC and PE. During the process of mast cell maturation in co-culture with fibroblasts, the AA released from mast cells by cPLA₂ α is transferred to adjacent fibroblasts for the synthesis of anti-allergic prostaglandin E₂ [58].

The wide range of biological roles attributed to cPLA₂ α has been extended by recent work implicating this enzyme in the selective production of lipid mediators during macrophage polarization to either M1 (pro-inflammatory) or M2 (anti-inflammatory) states. A recent study investigated the synthesis of lipid mediators released by macrophages treated with GM-CSF or M-CSF, which polarize the cells to M1 and M2 states, respectively [59]. While under unstimulated conditions both types of macrophages generate pro-resolving lipid mediators in a similar manner, upon cell stimulation with bacteria, M2 macrophages mobilize larger amounts of AA via increased cPLA₂ α activation, and generate more leukotriene C₄, resembling in this regard the M2-like cells in lung allergy [59]. These differences may be due, at least in part, to differences in the localization/compartimentalization of AA-metabolizing enzymes, which determine substrate accessibility. Consistent with these results, more recent work has also highlighted the different lipid mediator signatures of macrophages responding to bacteria, depending on whether they have been polarized to M1 or M2 [60]. Still, much work remains to be carried

out to clarify the compartmentalized regulation of enzymes participating in the synthesis of these lipid mediators, including cPLA₂α.

Previous studies demonstrated that cPLA₂α translocates to the phagosomal membrane during macrophage phagocytosis through mechanisms that, in humans, involve phosphorylation of the enzyme by c-Jun N-terminal kinases and membrane association via the cationic cluster of four lysine residues present at the catalytic domain of the enzyme (**Figure 2**) [50, 52, 61-65]. More recently, it has been shown that the N-terminal C2 domain of cPLA₂α is sufficient to support FcR-mediated phagocytosis [66]. Importantly, overexpression of a cPLA₂α mutant without a complete catalytic domain, and therefore without enzymatic activity, rescues FcR-mediated phagocytosis in cells from cPLA₂α^{-/-} mice [66]. Based on these data, the proposal was made that the C2 domain of cPLA₂α induces perturbation of the membrane phospholipid packing, potentially generating membrane bending that is necessary for phagosome formation in a manner independent of its enzymatic activity [66]. These studies are important in that they provide the first example of a biological function associated to cPLA₂α that does not depend on enzyme activity. It is also worth noting in this regard another recent study implicating cPLA₂α in the regulation of the tumor suppressor gene SIRT2 via mechanisms likely independent of the hydrolytic activity of the enzyme [67].

Related with the studies by Zizza *et al.* described above [66], work by Ward *et al.* [68] suggested that the C2 domain of cPLA₂α, which binds to zwitterionic membranes with high affinity in a Ca²⁺-dependent manner, has a high membrane remodeling activity, producing dramatic changes in membrane curvature consistent with the role of cPLA₂α in the formation of the phagosome. Of note, cPLA₂α has long been recognized to regulate the formation of cytoplasmic lipid droplets under different conditions [69-72], by mechanisms

likely implicating regulation of positive membrane curvature that is necessary for the nascent organelle to emerge from the endoplasmic reticulum [51].

Most recently, it has been described that cPLA₂ α activity contributes to the phagosomal escape of *Mycobacterium tuberculosis* [73, 74]. The enzyme appears to facilitate translocation of the microbe from the endosomal to the cytosolic compartment of human THP-1 macrophage-like cells, allowing survival of the microorganism inside the cells. In addition, it was shown that prostaglandin E₂ helps to eliminate *M. tuberculosis* by increasing the apoptosis of infected macrophages. Apoptotic bodies are then captured by dendritic cells that mediate cross-presentation of *M. tuberculosis* antigens to CD8⁺T cells to initiate adaptive responses [73, 75]. Interestingly, lipoxin A₄ increases necrotic processes in infected macrophages, which helps bacteria to evade adaptive immunity [75].

Work by Slatter *et al.* [76] has unveiled a new biological function of cPLA₂ α in metabolism, as a regulator of energy production by mitochondria. It was shown that, in thrombin-activated platelets, which produce large amounts of ATP via β -oxidation, cPLA₂ α activation promotes fatty acid release and the subsequent β -oxidation of both eicosanoids and fatty acids. The rate of β -oxidation of eicosanoids is balanced with the rate of its generation, limited by cPLA₂ α , thus forming a positive feedback loop that serves to provide energy, dampen negative effects of excess of eicosanoids or the requirement of ATP as a kinase substrate [76].

Another interesting metabolic role for cPLA₂ α was described in work by Peña *et al.* [77], where the enzyme was identified as an early key factor for adipocyte differentiation *in vitro*. Further, animals deficient in cPLA₂ α that were subjected to a high fat diet show a reduced capacity to increase body weight and fat mass, highlighting the important role of cPLA₂ α in regulating adipose tissue enlargement.

Ca²⁺- Independent group VIA phospholipase A₂ (iPLA₂-VIA)

iPLA₂-VIA, also often abbreviated as iPLA₂β, is perhaps one of the PLA₂ enzymes for which more functions have recently been proposed. The enzyme was first found to participate in the regulation of lysophospholipid levels within the Lands' cycle [78-80]. Later work demonstrated that iPLA₂-VIA is a multifaceted enzyme with multiple roles in cell physiology and pathophysiology [35, 81-84], being of special relevance in regulating intracellular signaling leading to insulin secretion [35], and phospholipid hydrolysis reactions during apoptosis [85-88].

Regarding eicosanoid production, iPLA₂-VIA appears, in general terms, not to play a major role in mediating this response in innate immunity and inflammation, as evidenced by the large number of studies highlighting the lack of effect of selective inhibition of the enzyme in stimulus-induced AA release in multiple immune cells [45, 48, 57, 89-97]. Rather, the involvement of iPLA₂-VIA in the eicosanoid response appears to be restricted to specific conditions which depend on cell type, stimulus or lipid mediator to be formed [58, 98-106]. In some of the latter studies a certain preference of iPLA₂-VIA for cleaving AA-containing ether phospholipids was noted [105, 106].

More recent work has demonstrated that iPLA₂-VIA participates in fatty acid remodeling reactions aimed at removing oxidized fatty acyl chains within cardiolipin molecular species [107]. This process, which can be regarded as a special case of the originally described phospholipid remodeling function of iPLA₂-VIA, and also agrees with previous observations that oxidation of membranes accelerates iPLA₂-VIA-catalyzed fatty acid release [28, 108], yields monolysocardiolipins that can be esterified back by new non-oxidized fatty acid. The reparation of oxidized phospholipids confers protection of β-cells against external injury [107]. It is interesting to note in this regard that the closely related enzyme iPLA₂-VIB (iPLA₂γ) has also been shown to play a major role in mediating the

release of oxidized acyl chains from oxidized cardiolipins, leading to the production of second messengers and the removal of toxic products derived from oxidative stress in mouse myocardium [109].

A major open question in the field of lipid mediators is the molecular nature of the PLA₂ enzyme involved in the release of DHA and related omega-3 fatty acids from phospholipids as a first committed step for the generation of SPMs. Although by analogy with AA it is often assumed that cPLA₂ α may serve this role, currently there is no direct evidence for this and, as discussed in the previous section, the *in vitro* specificity data are not revealing in this regard. Importantly, several recent studies provide evidence to suggest that iPLA₂-VIA may fulfill this role in brain. DHA is found at high concentrations in the *sn*-2 position of brain membrane phospholipids and is critical for maintaining normal brain structure, function and metabolism, participating in signal transduction, gene transcription, and membrane stability [110]. It has been shown that *Pla2g6*^{-/-} mice exhibit disturbances in brain lipid composition and metabolism, which are associated with reduced incorporation of unesterified DHA from plasma into brain lipids and reduced esterified DHA concentrations in lipid classes [111-113]. Because DHA is the precursor of anti-inflammatory SPMs, the reduced brain DHA metabolism in the *Pla2g6*^{-/-} mice may increase their vulnerability to neuroinflammation [114-117].

An unexpected result regarding the substrate selectivity of iPLA₂-VIA in cells has come from studies in mouse peritoneal macrophages [57]. Using pharmacological approaches and lipidomic strategies, evidence was obtained that cPLA₂ α and iPLA₂-VIA act on different phospholipid pools. While the former regulates AA release and eicosanoid production, the later acts on phospholipids that do not contain AA. iPLA₂-VIA appears to selectively hydrolyze choline glycerophospholipids with palmitic acid at the *sn*-1 position, resulting in the production of palmitate-containing lysoPC, a lysophospholipid species with

defined biological roles [85, 118] (**Figure 3**). Thus, iPLA₂-VIA also takes part in signaling cascades leading to the generation of lipid mediators. Interestingly, this selectivity of iPLA₂-VIA for PC containing palmitic acid at the *sn*-1 position had also been appreciated in a prior study utilizing iPLA₂-VIA-overexpressing HEK293 cells [119]. These two studies suggest more selectivity at the cellular level than observed for the *in vitro* selectivity of the pure recombinant human iPLA₂-VIA for the *sn*-1 fatty acid or phospholipid headgroup [24], pointing out the intriguing possibility that, in a physiological environment, iPLA₂-VIA could be compartmentalized in specific membranes enriched in palmitic acid-containing lipids.

Another interesting finding regarding substrate selectivity of iPLA₂-VIA in whole cellular systems stems from the observation that some of the major species hydrolyzed by the enzyme contain a 16:1 fatty acid at the *sn*-2 position [57, 119], raising the possibility that iPLA₂-VIA may constitute a major pathway for the mobilization of this fatty acid from membrane phospholipids. The most abundant 16:1 fatty acid of mammalian cells is palmitoleic acid (16:1*n*-7), and there is strong evidence that this free fatty acid possesses anti-inflammatory activity, and suppresses hepatic steatosis and improves insulin sensitivity in murine models of metabolic disease [120, 121]. Two isomers of palmitoleic acid, namely *cis*-7-hexadecenoic acid (16:1*n*-9) and sapienic acid (16:1*n*-10), were later identified in monocytes and macrophages [122, 123] and, at least the first one displays strong anti-inflammatory activity as well. Differences in the distribution of the three 16:1 isomers among membrane phospholipids were detected [122], suggesting that not all of them may be mobilized in a similar manner during activation and that the multiplicity of effects initially attributed to palmitoleic acid may reflect the overlapping actions of several 16:1 isomers acting in concert at the same locations. It is also notorious the discovery of a novel family of anti-inflammatory lipids that results from the esterification of the hydroxyl group of a hydroxy fatty acid with another fatty acid (collectively termed "branched fatty acid esters of

hydroxy fatty acids”, FAHFAs) [124-128]. The hydroxyfatty acids forming FAHFAs possess 16 or 18 carbon atoms. Little is yet known of their biosynthesis, but it has been shown that they are produced endogenously, thus it is tempting to speculate that the 16-carbon containing ones could derive from hydration of different isomers of 16:1 fatty acids.

Another important new result that has expanded the range of functions of iPLA₂-VIA in physiology and pathophysiology is its implication in macrophage polarization under stimulation conditions. Ashley *et al.* [129] described in peritoneal macrophages from Pla2g6^{-/-} mice that the absence of iPLA₂-VIA facilitates macrophage polarization towards an anti-inflammatory M2 state, and modulates the expression of several enzymes involved in the synthesis of eicosanoid and reactive oxygen species. Conversely, the activation of genes involved in polarization to a pro-inflammatory M1 state is blunted in Pla2g6^{-/-} macrophages. Overall, these results support a scenario where macrophage polarization may be dependent on signaling lipid molecules generated by PLA₂s [129].

Regarding novel roles for iPLA₂-IVA in metabolism, Deng *et al.* [130] recently demonstrated in Pla2g6^{-/-} mice that the lack of the enzyme protects genetic obese mice from obesity and hepatic steatosis. The data support the notion that iPLA₂-VIA has a pathophysiological function via phospholipid remodeling which ultimately results in the depletion of polyunsaturated fatty acids from PC and PE, especially those molecular species that carry palmitic or stearic acids at the *sn*-1 position. Inactivation of iPLA₂-VIA reverses remodeling and establishes the return to normal homeostasis [130].

Group V phospholipase A₂ (sPLA₂-V)

An abundant body of work dating back from the 90's has documented the involvement of sPLA₂-V in AA mobilization and attendant eicosanoid production [131]. In general terms, sPLA₂-V acts by amplifying the action of cPLA₂α, which is the key enzyme in the process,

via activity-dependent or -independent mechanisms. sPLA₂-V shows no clear fatty acid preference [24], and is able to release other fatty acids from cells, *e.g.* oleic acid or linoleic acid [132-134], with regulatory features that are strikingly similar to those of AA release. From these results it can be inferred that sPLA₂-V may also be implicated in lipid metabolic pathways distinct from canonical AA signaling to exert its biological actions *in vivo*.

Several recent reviews have appeared covering different aspects of the sPLA₂ family of enzymes, including sPLA₂-V, and the interested reader is kindly directed to these for specific details [34, 135-137]. It is important to remark here, however, that recent studies on sPLA₂-V suggest that some of the biological functioning of the enzyme is context- and even species-specific [34]. This is an important concept to take into account, because a considerable part of results regarding the role of sPLA₂-V in pathophysiology have come from studies in mice, and the availability of the sPLA₂-V knockout mouse model has provided much valuable insight [46, 138]. However, the human enzyme differs from the mouse enzyme in at least one key aspect. In mouse peritoneal macrophages, sPLA₂-V translocates to the phagosome after ingestion of zymosan and regulates phagocytosis by mechanisms that may or may not depend on eicosanoid synthesis [139, 140]. Under similar experimental conditions, however, the enzyme does not translocate to the phagosome in humans [61, 62]. These data suggest that, at least in humans, the regulatory actions of the enzyme on the phagocytosis process itself occur at a level distinct from that of the phagosome, perhaps at the plasma membrane level. Interestingly however, it was recognized that the regulation of phagocytosis by sPLA₂-V in human and murine cells may actually lead to similar outcomes, *i.e.* in both systems sPLA₂-V favors the phagocytosis process, thus helps to resolve inflammation [139-141].

A recent lipidomic analysis determined that the increased expression of sPLA₂-V in interleukin-4-treated macrophages is selectively linked to increased levels of cellular

ethanolamine lysophospholipids (LPE) [141]. These lipid molecules are necessary to support the elevated phagocytic response that these cells exhibit in response to both zymosan particles and live bacteria. The addition of exogenous LPE fully restores phagocytosis in sPLA₂-V-deficient cells, and overexpression of the enzyme produces a significant increase of the phagocytic capacity of the cells. It is possible that sPLA₂-V acts on the plasma membrane, and the accumulation of LPE alters the structure and fluidity of a variety of microdomains, including lipid rafts, favoring oligomerization/interaction of phagocytic receptors. Thus LPE may help develop further signaling, eventually favoring repair mechanisms and the return to homeostasis (**Figure 2**). It has recently been discovered that ethanolamine lysoplasmalogens are, among LPE molecular species, the ones producing the largest effect (J. Rubio and J. Balsinde, unpublished data), pointing out again the importance of specific lipids in regulating innate immune functions. It is worth mentioning in this regard that another member of the sPLA₂ family, sPLA₂-IIF, was described earlier to cleave ethanolamine plasmalogens, generating lysoplasmalogen in keratinocytes, which is a biomarker of skin diseases [142]. Since ethanolamine phospholipids reside primarily in the inner leaflet of the plasma membrane, a scenario such as the one described above would be fully consistent with the large body of literature indicating that, after secretion of sPLA₂-V to the extracellular medium, the enzyme re-associates with the plasma membrane and, subsequently, is re-internalized by different mechanisms, including interaction of the enzyme with heparan sulfate proteoglycans [143] or caveolin-rich domains [144, 145]. This could bring the enzyme into proximity with ethanolamine phospholipid pools at the inner leaflet to regulate specific cellular responses (**Figure 2**) [131, 146, 147]. Thus, sPLA₂-V may act in an autocrine or paracrine fashion at different subcellular locations in the cell, depending on cell type and the nature of the activating stimulus.

Interestingly, anti-inflammatory actions for sPLA₂-V were also described in mice a few years ago in a model of autoimmune complex mediated arthritis. [148]. A novel mechanism was delineated, whereby sPLA₂-V promotes phagocytosis of immune complexes by macrophages to ameliorate inflammation in autoimmune inflammatory arthritis. This function of sPLA₂-V appears to strikingly depend on enzymatic activity [148].

More recent studies have correlated sPLA₂-V with alternative macrophage activation (M2) in human and murine macrophages [149, 150]. sPLA₂-V expression was induced during both human and mouse interleukin-4-mediated activation of macrophages *in vitro*, and its absence impaired macrophage activation *in vivo*. The elimination or depletion of sPLA₂-V from the macrophages of both species selectively reduces the expression of CCL22/CCL17 that determines effector T cell recruitment and eosinophilic inflammation. Collectively, these findings suggest that sPLA₂-V contributes to the Th2-dependent response for polarized activation of macrophages and that this function is conserved across species. Such a role is in intriguing contrast with earlier results suggesting that stimuli that polarize macrophages to M1 such as LPS, are also able to significantly up-regulate sPLA₂-V in several mouse tissues [151] and the transformed murine macrophage-like cell lines P388D₁ [152] and RAW264.7 (J. Rubio and J. Balsinde, unpublished results). As discussed elsewhere [34], it is possible that sPLA₂-V may be a bi-faceted enzyme with both pro- and anti-inflammatory (“Th2-prone”) roles depending on conditions, cell types, and species.

Apart from its roles in innate immunity, sPLA₂-V is also suggested to participate in the progression of atherosclerosis. The enzyme is found in human atherosclerotic lesions, and hydrolyzes low-density-lipoprotein phospholipids in a way that the modified lipoproteins promote foam cell formation. However, there is not always an agreement on whether sPLA₂-V affects positively or negatively the cardiovascular process [153, 154].

The hydrolysis of PC by sPLA₂-V seems to be favored in obesity, where adipocyte-released sPLA₂-V hydrolyzes excess PC of low density lipoproteins from animals fed a high fat diet, eventually protecting from hyperlipidemia. This links sPLA₂-V with energy metabolism, as seen in obese *Pla2g5*^{-/-} mice and in human white adipose tissue, where *PLA2G5* expression inversely correlates with plasma low density lipoprotein levels [150]. The explanation is that the the hydrolysis of low density lipoprotein particles produces unsaturated free fatty acids such as oleic or linoleic acid, which shift M1 to M2 macrophages or prevent palmitic acid-induced M1 macrophage polarization [150].

Group X phospholipase A₂ (sPLA₂-X)

Of all members of the sPLA₂ family of enzymes, sPLA₂-X is the one that shows the highest activity towards PC [155]. The enzyme is long known to release various fatty acids including AA and oleic acid, and increases prostaglandin E₂ production when added exogenously to phagocytic cells, suggesting a role for this enzyme in inflammation [156]. Later, its role in inflammatory lung diseases, both mouse and human, was defined [157-161]. More recently, using an inhaled allergen model, Nolin *et al.* [162] demonstrated that *Pla2g10*^{-/-} mice are protected from developing allergic airway disease, altering the polarization of macrophages to an M2 state. These results point out to a critical function for sPLA₂-X in both the innate and adaptive immune response to inhaled allergens in human and mice. Other studies have described the involvement of sPLA₂-X in regulating the formation of cysteinyl leukotrienes in neutrophils by mechanisms involving cross talk with cPLA₂α [163, 164].

Aside from the ability of sPLA₂-X to effect AA mobilization from a variety of cells [143, 155, 156], some recent studies have also described the ability of the enzyme to liberate DHA and other omega-3 fatty acids [133]. sPLA₂-X would effect the release of all omega-3

fatty acids, *i.e.* DHA, DPA and EPA preferentially over that of AA, placing this enzyme as another possible regulator of anti-inflammatory pro-resolving pathways [36]. In keeping with this notion, other works have attributed anti-inflammatory properties to sPLA₂-X in the development of atherosclerosis by limiting Th-1 responses or adipogenesis in murine models of obesity [165, 166].

On the opposite side, sPLA₂-X has also been implicated in the pathology of cancer [167, 168]. Human sPLA₂-X induces lipid droplet formation in *Ras*-driven MDA-MB-231 triple-negative breast cancer cells and promotes their survival during nutrient stress. It acts through the products of its enzymatic activity, most likely by providing mono- and polyunsaturated free fatty acids from cell membrane phospholipids for triacylglycerol synthesis that favor lipid droplet formation and reduces the requirement for *de novo* lipogenesis, protecting the cell against lipotoxicity and nutrient deprivation [167, 168].

Other phospholipase A₂s

Oxidized phospholipids are formed from unsaturated acyl residues under oxidative stress in lipid membranes [169, 170]. Oxidized phospholipids are frequently found in vascular tissues and lipoproteins, and usually contain an oxovaleroyl or glutaroyl residue at the *sn*-2 position, which result from the truncation and oxidation of an AA or EPA residue at C5. Traditionally, two PLA₂ enzymes were thought to hydrolyze truncated phospholipids, namely PAF acetylhydrolase I (group VIIA PLA₂), which is associated to lipoproteins, and PAF acetylhydrolase II (group VIIB PLA₂), which acts intracellularly. Recent work has demonstrated that a third PLA₂, the lysosomal PLA₂ (group XV PLA₂) is also able to cleave oxidized phospholipids, thus uncovering a new catabolic pathway for the clearance of these molecules [171].

Recent work by Shimanaka *et al.* [172] has unveiled a novel and unexpected role for PAF acetyl hydrolase II in regulating the production of a novel class of omega-3 epoxides in mast cells with key roles in mast cell activation and anaphylaxis. These epoxy omega-3 fatty acids are stored as esterified forms in membrane choline glycerophospholipids. Using bone marrow-derived mast cells from *Pafah2*^{-/-} mice, it was demonstrated that PAF acetyl hydrolase II is the specific enzyme that excises the epoxides away from the membrane. This way, PAF acetyl hydrolase II initiates a novel signaling cascade mediated by epoxy omega-3 mediators that optimizes FcεRI-dependent mast cell activation [172].

Novel functions for other sPLA₂s have been described based on the lipid that they generate. sPLA₂-IIE acts preferentially on minor lipoprotein phospholipids, phosphatidylserine (PS) and PE [150]. sPLA₂-IID has been found to release DHA from PE in lymph node membranes, suggesting that this enzyme may also constitute another “resolving sPLA₂” that ameliorates inflammation through mobilizing DHA-derived pro-resolving lipid mediators [173]. Conversely, sPLA₂-IIA has recently been described to target phospholipids in extracellular mitochondria that are released from activated platelets or leukocytes to accumulate at inflamed sites, thereby amplifying inflammation [174].

CoA-independent transacylation reactions

The most common forms of membrane glycerophospholipids contain two acyl chains attached to the *sn*-1 and *sn*-2 positions of the glycerol backbone by ester bonds. However there are glycerophospholipids that possess an *sn*-1 ether bond instead of an ester bond. Additionally, some of these ether-containing phospholipids also possess a *cis* double bond that is conjugated with the ether oxygen, *i.e.* forming a vinyl ether (**Figure 4**). These phospholipids are called plasmalogens. In humans, plasmalogens constitute about 20% of total phospholipid content [175], but their biological roles are still to be fully recognized.

Because of the lack of a carbonyl group at the *sn*-1 position, plasmalogens allow for a tighter packing of phospholipids in the membrane, which results in decreased membrane fluidity, and favor the formation and stabilization of membrane lipid raft domains with key roles in cellular signaling. Plasmalogens are also thought to act as endogenous antioxidants [175, 176]. Only two major kinds of plasmalogens are found in mammalian cells, i.e. those containing either choline or ethanolamine as headgroups [177, 178]. Inositol-containing plasmalogens have also been described but their levels are exceedingly low [179]. While heart contains relatively high amounts of choline plasmalogens, ethanolamine plasmalogens are particularly abundant in innate immune cells such as monocytes and macrophages. Notably, in these cells, practically only polyunsaturated fatty acids of both the omega-6 and omega-3 series are to be found at the *sn*-2 position of ethanolamine plasmalogens, with AA being the most prevalent one (**Figure 4**). Owing to such fatty acid composition, the importance of this class of lipids to PLA₂-regulated pathways leading to generation of lipid mediators has long been recognized.

Mammalian cells contain significant amounts of a relatively lesser known enzyme that shows marked specificity for ether lipids containing AA and other 20-22 carbon fatty acids. This enzyme is called CoA-independent transacylase (CoA-IT), and transfers polyunsaturated moieties of 20-22 carbons, typically AA, from diacyl PC species to ether phospholipids, particularly the ethanolamine plasmalogens. This reaction is considered of special relevance not only for the maintenance of membrane homeostasis but also for ensuring the appropriate distribution of AA among the various phospholipid pools for the execution of PLA₂-dependent responses during immune cell activation [15, 25, 93, 178, 180-187]. Thus, CoA-IT is regarded as a key enzyme for the regulation of polyunsaturated fatty acid mobilization reactions in major immunoinflammatory cells. The rapid remodeling of AA moieties to ethanolamine plasmalogens during cell stimulation explains why in many

instances, when measuring AA mobilization by mass in activated cells, no changes in the AA content of PE molecular species is observed, despite PE constituting the richest AA-containing class. The CoA-IT reaction prevents a decline of AA in the cellular amount of PE during cellular stimulation by channeling AA to PE from PC [2, 54, 55, 57].

The CoA-IT sequence is presently unknown, making it one of the 1078 orphan enzymes currently listed in the ORENZA database (EC 2.3.2.147) [188]. Thus, presently the only way to study of CoA-IT is by measuring its enzyme activity or by pharmacological means [57, 189-192]. The importance of CoA-IT in regulating the proper distribution of AA within phospholipids appears so relevant that, when its activity is blunted, the profile of eicosanoids generated by mouse peritoneal macrophages under activation conditions changes [57]. By directing AA from PC toward PE, CoA-IT modulates the relative amount of lipoxygenase products formed, thus suggesting that certain cellular AA phospholipid pools are selectively linked to the formation of specific eicosanoids [57]. This concept, first suggested by the work of Chilton in neutrophils [193] implies the existence of a third regulatory step of the eicosanoid biosynthetic response, *i.e.* at the level of fatty acid compartmentalization within the cell. CoA-IT, by helping to place precursor fatty acids in the appropriate cellular pools decisively influences the eicosanoid response because not all these pools may be equally accessible to the relevant PLA₂ involved.

CoA-IT is not a PLA₂ in a strict sense because it does not generate a free fatty acid as a product, but it does cleave the *sn*-2 position of a phospholipid. This has led to the consideration of whether CoA-IT is actually a PLA₂ “in disguise”, *i.e.* that the CoA-IT reaction represents just an uncharacterized activity of an otherwise described PLA₂ enzyme. As a matter of fact, some well characterized PLA₂s, *e.g.* cPLA₂ α or iPLA₂-VIA, exhibit Ca²⁺-independent transacylase activity *in vitro* [16]. Early work in macrophages utilizing PLA₂ inhibitors of known specificity failed to relate CoA-IT activity to any of the PLA₂

group types that had been characterized at that time (iPLA₂-VIA, cPLA₂α, or sPLA₂-V) [93]. Consistent with these results, a subsequent study confirmed that neither cPLA₂α, nor iPLA₂-VIA nor sPLA₂-V were involved in AA phospholipid remodeling in peripheral blood T cells [181]. More recent studies have contemplated the possibility that CoA-IT activity may belong to cPLA₂γ (group IVC PLA₂) [194-196]. Despite being a group IV enzyme, cPLA₂γ is actually Ca²⁺-independent because it lacks the C2 domain present in the other group IV members [16]. However, the lysophospholipase activity of cPLA₂γ is considerably higher than its CoA-independent transacylation activity, which casts doubt as to whether this enzyme is actually responsible for moving AA from PC to PE in cells [194, 195].

Because of the lack of sequence, current knowledge on the cellular regulation of CoA-IT is scarce. However, recent work has suggested an interesting new role for CoA-IT in regulating the extent of the AA mobilization response in primed macrophages. Bacterial lipopolysaccharide (LPS) is a poor trigger of AA mobilization in macrophages but has the capacity to greatly increase the response upon a subsequent cellular stimulation. Gil-de-Gómez *et al.* [197] recently showed that LPS priming of macrophages is strikingly associated with an increased hydrolysis of ethanolamine plasmalogens by cPLA₂α, which is due, at least in part, to diminished recycling of AA into this particular species via CoA-IT-mediated transacylation reactions. Reduced CoA-IT activity after LPS priming could bear important pathological consequences because it may lead to excessive damage arising from an exacerbated production of eicosanoids subsequent to the increased availability of free AA [197]. An important unanswered question that stems from these observations is whether the priming effect is exerted directly on the CoA-IT enzyme itself or rather by impacting on an unrecognized effector that regulates upstream events such as the proper access of the enzyme to its substrate. The latter scenario would be analogous to that described for CoA-IT

regulation of platelet-activating factor synthesis in human neutrophils, which depended upon substrate availability, not increased enzyme activity [198].

Another important regulator of CoA-IT-mediated reactions that has recently been unveiled is the cellular level of esterified AA in membranes. It has been known for some time that phospholipid AA remodeling is much faster in cell lines than that in their counterpart physiologic cells. For example, complete AA transfer from PC to PE generally takes hours in murine macrophages or human monocytes, while it takes only minutes in the murine macrophage-like cell line P388D₁ or the human monocyte-like cell line U937 [15, 25, 189, 197, 199, 200].

Astudillo *et al.* [189] demonstrated that cellular AA levels determine the amount of CoA-independent transacylase activity expressed by cells; the lower the levels of cellular AA, the higher the extent of cellular CoA-IT activity [189]. The mechanism through which this occurs remains to be elucidated but, since simply enriching the cells with AA reduces the measurable CoA-IT activity of homogenates, it seems likely that an unidentified AA metabolite or AA-containing phospholipid that is present in the AA-enriched cells may act to regulate the expression levels of CoA-IT [189].

Concluding Remarks

Much progress has been made in recent years to understand the cellular regulation of the selective hydrolysis of membrane phospholipids by PLA₂s. Still, the different activation conditions and the accessibility to different pools in the cell may lead to the production of yet unidentified lipid mediators that participate in crucial pathophysiological events. It is important to emphasize that PLA₂ represents the very first step of signaling pathways that involve lipid mediators which act *per se* or may be further metabolized to other bioactive compounds. The definition of molecular mechanisms governing the catalytic activity and

substrate preference of the various cellular PLA₂s under stimulation conditions is a very significant yet still unexplored field.

Acknowledgments

Work in the authors' laboratory was supported by Grants SAF2016-80883-R and SAF2015-73000-EXP from the Spanish Ministry of Economy, Industry and Competitiveness, and Grant CSI073U16 from the Education Department of the Regional Government of Castile and Leon. CIBERDEM is an initiative of Instituto de Salud Carlos III.

References

- [1] A.M. Astudillo, D. Balgoma, M.A. Balboa, J. Balsinde, Dynamics of arachidonic acid mobilization by inflammatory cells, *Biochim. Biophys. Acta* 1821 (2012) 249-256.
- [2] C.A. Rouzer, P.T. Ivanova, M.O. Byrne, H.A. Brown, L.J. Marnett, Lipid profiling reveals glycerophospholipid remodeling in zymosan-stimulated macrophages, *Biochemistry* 46 (2007) 6026-6042.
- [3] W.A. Scott, J.M. Zrike, A.L. Hamill, J. Kempe, Z.A. Cohn, Regulation of arachidonic acid metabolites in macrophages, *J. Exp. Med.* 152 (1980) 324-335.
- [4] C.D. Funk, Prostaglandins and leukotrienes: advances in eicosanoid biology, *Science* 294 (2001) 1871-1875.
- [5] J.W. Phillis, L.A. Horrocks, A.A. Farooqui, Cyclooxygenases, lipoxygenases, and epoxigenases in CNS: their role and involvement in neurological disorders, *Brain Res. Rev.* 52 (2006) 201-243.
- [6] A.C. Araujo, C.E. Wheelock, J.Z. Haeggstrom, The eicosanoids, redox-regulated lipid mediators in immunometabolic disorders, *Antioxid. Redox Signal.* 29 (2018) 275-296.
- [7] E. Ricciotti, G.A. FitzGerald, Prostaglandins and inflammation, *Arterioscler. Thromb. Vasc. Biol.* 31 (2011) 986-1000.
- [8] M. Peters-Golden, C. Canetti, P. Mancuso, M.J. Coffey, Leukotrienes: underappreciated mediators of innate immune responses, *J. Immunol.* 174 (2005) 589-594.
- [9] P. Kalinski, Regulation of immune responses by prostaglandin E₂, *J. Immunol.* 188 (2012) 21-28.
- [10] C.N. Serhan, Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways, *Annu. Rev. Immunol.* 25 (2007) 101-137.
- [11] C.N. Serhan, Pro-resolving lipid mediators are leads for resolution physiology, *Nature* 510 (2014) 92-101.
- [12] D.Y. Oh, S. Talukdar, E.J. Bae, T. Imamura, H. Morinaga, W. Fan, P. Li, W.J. Lu, S.M. Watkins, J.M. Olefsky, GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects, *Cell* 142 (2010) 687-698.
- [13] Q.N. Diep, R.M. Touyz, E.L. Schiffrin, Docosahexaenoic acid, a peroxisome proliferator-activated receptor- α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase, *Hypertension* 36 (2000) 851-855.
- [14] E.A. Dennis, P.C. Norris, Eicosanoid storm in infection and inflammation, *Nat. Rev. Immunol.* 15 (2015) 511-523.
- [15] G. Pérez-Chacón, A.M. Astudillo, D. Balgoma, M.A. Balboa, J. Balsinde, Control of free arachidonic acid levels by phospholipases A₂ and lysophospholipid acyltransferases, *Biochim. Biophys. Acta* 1791 (2009) 1103-1113.
- [16] E.A. Dennis, J. Cao, Y.H. Hsu, V. Magriotti, G. Kokotos, Phospholipase A₂ enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention, *Chem. Rev.* 111 (2011) 6130-6185.
- [17] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, K. Yamamoto, Recent progress in phospholipase A₂ research: from cells to animals to humans, *Prog. Lipid Res.* 50 (2011) 152-192.

- [18] J.E. Burke, E.A. Dennis, Phospholipase A₂ structure/function, mechanism, and signaling, *J. Lipid Res.* 50 Suppl (2009) S237-S242.
- [19] R.H. Schaloske, E.A. Dennis, The phospholipase A₂ superfamily and its group numbering system, *Biochim. Biophys. Acta* 1761 (2006) 1246-1259.
- [20] D.A. Six, E.A. Dennis, The expanding superfamily of phospholipase A₂ enzymes: classification and characterization, *Biochim. Biophys. Acta* 1488 (2000) 1-19.
- [21] K.C. Batchu, S. Hanninen, S.K. Jha, M. Jeltsch, P. Somerharju, Factors regulating the substrate specificity of cytosolic phospholipase A₂ α in vitro, *Biochim. Biophys. Acta* 1861 (2016) 1597-1604.
- [22] K.C. Batchu, K. Hokynar, M. Jeltsch, K. Mattonet, P. Somerharju, Substrate efflux propensity is the key determinant of Ca²⁺-independent phospholipase A₂ β (iPLA₂ β)-mediated glycerophospholipid hydrolysis, *J. Biol. Chem.* 290 (2015) 10093-10103.
- [23] P. Haimi, M. Hermansson, K.C. Batchu, J.A. Virtanen, P. Somerharju, Substrate efflux propensity plays a key role in the specificity of secretory A-type phospholipases, *J. Biol. Chem.* 285 (2010) 751-760.
- [24] V.D. Mouchlis, Y. Chen, J.A. McCammon, E.A. Dennis, Membrane allostery and unique hydrophobic sites promote enzyme substrate specificity, *J. Am. Chem. Soc.* 140 (2018) 3285-3291.
- [25] F.H. Chilton, A.N. Fonteh, M.E. Surette, M. Triggiani, J.D. Winkler, Control of arachidonate levels within inflammatory cells, *Biochim. Biophys. Acta* 1299 (1996) 1-15.
- [26] H. Shindou, M. Eto, R. Morimoto, T. Shimizu, Identification of membrane O-acyltransferase family motifs, *Biochem. Biophys. Res. Commun.* 383 (2009) 320-325.
- [27] H. Shindou, D. Hishikawa, T. Harayama, K. Yuki, T. Shimizu, Recent progress on acyl CoA: lysophospholipid acyltransferase research, *J. Lipid Res.* 50 Suppl (2009) S46-S51.
- [28] M.A. Balboa, J. Balsinde, Oxidative stress and arachidonic acid mobilization, *Biochim. Biophys. Acta* 1761 (2006) 385-391.
- [29] J. Balsinde, M.V. Winstead, E.A. Dennis, Phospholipase A₂ regulation of arachidonic acid mobilization, *FEBS Lett.* 531 (2002) 2-6.
- [30] C.N. Serhan, N. Chiang, J. Dalli, New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration, *Mol. Aspects Med.* (2017) in press.
- [31] C.N. Serhan, N. Chiang, T.E. Van Dyke, Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators, *Nat. Rev. Immunol.* 8 (2008) 349-361.
- [32] C.N. Serhan, K. Gotlinger, S. Hong, M. Arita, Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis, *Prostaglandins Other Lipid Mediat.* 73 (2004) 155-172.
- [33] C.C. Leslie, Cytosolic phospholipase A₂: physiological function and role in disease, *J. Lipid Res.* 56 (2015) 1386-1402.
- [34] M. Murakami, H. Sato, Y. Miki, K. Yamamoto, Y. Taketomi, A new era of secreted phospholipase A₂, *J. Lipid Res.* 56 (2015) 1248-1261.
- [35] S. Ramanadham, T. Ali, J.W. Ashley, R.N. Bone, W.D. Hancock, X. Lei, Calcium-independent phospholipases A₂ and their roles in biological processes and diseases, *J. Lipid Res.* 56 (2015) 1643-1668.

- [36] R. Murase, H. Sato, K. Yamamoto, A. Ushida, Y. Nishito, K. Ikeda, T. Kobayashi, T. Yamamoto, Y. Taketomi, M. Murakami, Group X secreted phospholipase A₂ releases omega3 polyunsaturated fatty acids, suppresses colitis, and promotes sperm fertility, *J. Biol. Chem.* 291 (2016) 6895-6911.
- [37] M. Shikano, Y. Masuzawa, K. Yazawa, K. Takayama, I. Kudo, K. Inoue, Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A₂ during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine, *Biochim. Biophys. Acta* 1212 (1994) 211-216.
- [38] R.M. Kramer, J.D. Sharp, Structure, function and regulation of Ca²⁺-sensitive cytosolic phospholipase A₂ (cPLA₂), *FEBS Lett.* 410 (1997) 49-53.
- [39] J.V. Bonventre, Z. Huang, M.R. Taheri, E. O'Leary, E. Li, M.A. Moskowitz, A. Sapirstein, Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A₂, *Nature* 390 (1997) 622-625.
- [40] H. Fujishima, R.O. Sánchez Mejía, C.O. Bingham, 3rd, B.K. Lam, A. Sapirstein, J.V. Bonventre, K.F. Austen, J.P. Arm, Cytosolic phospholipase A₂ is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells, *Proc. Natl. Acad. Sci. U.S.A.* 96 (1999) 4803-4807.
- [41] M.A. Gijón, D.M. Spencer, A.R. Siddiqi, J.V. Bonventre, C.C. Leslie, Cytosolic phospholipase A₂ is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A₂ regulation, *J. Biol. Chem.* 275 (2000) 20146-20156.
- [42] N. Uozumi, K. Kume, T. Nagase, N. Nakatani, S. Ishii, F. Tashiro, Y. Komagata, K. Maki, K. Ikuta, Y. Ouchi, J. Miyazaki, T. Shimizu, Role of cytosolic phospholipase A₂ in allergic response and parturition, *Nature* 390 (1997) 618-622.
- [43] M. Murakami, S. Shimbara, T. Kambe, H. Kuwata, M.V. Winstead, J.A. Tischfield, I. Kudo, The functions of five distinct mammalian phospholipase A₂s in regulating arachidonic acid release. Type IIA and type V secretory phospholipase A₂s are functionally redundant and act in concert with cytosolic phospholipase A₂, *J. Biol. Chem.* 273 (1998) 14411-14423.
- [44] J. Balsinde, M.A. Balboa, E.A. Dennis, Functional coupling between secretory phospholipase A₂ and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A₂, *Proc. Natl. Acad. Sci. U.S.A.* 95 (1998) 7951-7956.
- [45] W.K. Han, A. Sapirstein, C.C. Hung, A. Alessandrini, J.V. Bonventre, Cross-talk between cytosolic phospholipase A₂α (cPLA₂α) and secretory phospholipase A₂ (sPLA₂) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA₂ regulates cPLA₂α activity that is responsible for arachidonic acid release, *J. Biol. Chem.* 278 (2003) 24153-24163.
- [46] Y. Satake, B.L. Díaz, B. Balestrieri, B.K. Lam, Y. Kanaoka, M.J. Grusby, J.P. Arm, Role of group V phospholipase A₂ in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption, *J. Biol. Chem.* 279 (2004) 16488-16494.
- [47] E. Kikawada, J.V. Bonventre, J.P. Arm, Group V secretory PLA₂ regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA₂α activation, *Blood* 110 (2007) 561-567.
- [48] V. Ruipérez, A.M. Astudillo, M.A. Balboa, J. Balsinde, Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A₂s, *J. Immunol.* 182 (2009) 3877-3883.

- [49] V. Ruipérez, J. Casas, M.A. Balboa, J. Balsinde, Group V phospholipase A₂-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages, *J. Immunol.* 179 (2007) 631-638.
- [50] M.A. Balboa, R. Pérez, J. Balsinde, Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A₂ is regulated by cytosolic phospholipase A₂-derived hydroperoxyeicosatetraenoic acid, *J. Immunol.* 171 (2003) 989-994.
- [51] C. Guijas, J.P. Rodríguez, J.M. Rubio, M.A. Balboa, J. Balsinde, Phospholipase A₂ regulation of lipid droplet formation, *Biochim. Biophys. Acta* 1841 (2014) 1661-1671.
- [52] M. Ghosh, D.E. Tucker, S.A. Burchett, C.C. Leslie, Properties of the Group IV phospholipase A₂ family, *Prog. Lipid Res.* 45 (2006) 487-510.
- [53] C.C. Leslie, T.A. Gangelhoff, M.H. Gelb, Localization and function of cytosolic phospholipase A₂ α at the Golgi, *Biochimie* 92 (2010) 620-626.
- [54] L. Gil-de-Gómez, A.M. Astudillo, C. Meana, J.M. Rubio, C. Guijas, M.A. Balboa, J. Balsinde, A phosphatidylinositol species acutely generated by activated macrophages regulates innate immune responses, *J. Immunol.* 190 (2013) 5169-5177.
- [55] D. Balgoma, A.M. Astudillo, G. Pérez-Chacón, O. Montero, M.A. Balboa, J. Balsinde, Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids, *J. Immunol.* 184 (2010) 3857-3865.
- [56] D. Balgoma, O. Montero, M.A. Balboa, J. Balsinde, Calcium-independent phospholipase A₂-mediated formation of 1,2-diarachidonoyl-glycerophosphoinositol in monocytes, *FEBS J.* 275 (2008) 6180-6191.
- [57] L. Gil-de-Gómez, A.M. Astudillo, C. Guijas, V. Magriotti, G. Kokotos, M.A. Balboa, J. Balsinde, Cytosolic group IVA and calcium-independent group VIA phospholipase A₂s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages, *J. Immunol.* 192 (2014) 752-762.
- [58] N. Ueno, Y. Taketomi, K. Yamamoto, T. Hirabayashi, D. Kamei, Y. Kita, T. Shimizu, K. Shinzawa, Y. Tsujimoto, K. Ikeda, R. Taguchi, M. Murakami, Analysis of two major intracellular phospholipase A₂s in mast cells reveals crucial contribution of cPLA₂ α , not iPLA₂ β , to lipid mobilization in proximal mast cells and distal fibroblasts, *J. Biol. Chem.* 286 (2011) 37249-37263.
- [59] A. Lukic, P. Larssen, A. Fauland, B. Samuelsson, C.E. Wheelock, S. Gabrielsson, O. Radmark, GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures, *FASEB J.* 31 (2017) 4370-4381.
- [60] O. Werz, J. Gerstmeier, S. Libreros, X. De la Rosa, M. Werner, P.C. Norris, N. Chiang, C.N. Serhan, Human macrophages differentially produce specific resolvins or leukotriene signals that depend on bacterial pathogenicity, *Nat. Commun.* 9 (2018) 59.
- [61] J. Casas, C. Meana, E. Esquinas, M. Valdearcos, J. Pindado, J. Balsinde, M.A. Balboa, Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A₂ to phagosomes in human macrophages, *J. Immunol.* 183 (2009) 2767-2774.
- [62] J. Casas, M. Valdearcos, J. Pindado, J. Balsinde, M.A. Balboa, The cationic cluster of group IVA phospholipase A₂ (Lys⁴⁸⁸/Lys⁵⁴¹/Lys⁵⁴³/Lys⁵⁴⁴) is involved in translocation of the enzyme to phagosomes in human macrophages, *J. Lipid Res.* 51 (2010) 388-399.
- [63] J. Casas, M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, M.A. Balboa, Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A₂ to

perinuclear membranes and decreases its calcium requirement for translocation in live cells, *Mol. Biol. Cell* 17 (2006) 155-162.

[64] D.E. Tucker, M. Ghosh, F. Ghomashchi, R. Loper, S. Suram, B.S. John, M. Girotti, J.G. Bollinger, M.H. Gelb, C.C. Leslie, Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A₂α in regulating interfacial kinetics and binding and cellular function, *J. Biol. Chem.* 284 (2009) 9596-9611.

[65] M. Girotti, J.H. Evans, D. Burke, C.C. Leslie, Cytosolic phospholipase A₂ translocates to forming phagosomes during phagocytosis of zymosan in macrophages, *J. Biol. Chem.* 279 (2004) 19113-19121.

[66] P. Zizza, C. Iurisci, M. Bonazzi, P. Cossart, C.C. Leslie, D. Corda, S. Mariggio, Phospholipase A₂IVα regulates phagocytosis independent of its enzymatic activity, *J. Biol. Chem.* 287 (2012) 16849-16859.

[67] S. Movahedi Naini, A.M. Sheridan, T. Force, J.V. Shah, J.V. Bonventre, Group IVA cytosolic phospholipase A₂ regulates the G2-to-M transition by modulating the activity of tumor suppressor SIRT2, *Mol. Cell Biol.* 35 (2015) 3768-3784.

[68] K.E. Ward, J.P. Ropa, E. Adu-Gyamfi, R.V. Stahelin, C2 domain membrane penetration by group IVA cytosolic phospholipase A₂ induces membrane curvature changes, *J. Lipid Res.* 53 (2012) 2656-2666.

[69] A. Gubern, M. Barceló-Torns, J. Casas, D. Barneda, R. Masgrau, F. Picatoste, J. Balsinde, M.A. Balboa, E. Claro, Lipid droplet biogenesis induced by stress involves triacylglycerol synthesis that depends on group VIA phospholipase A₂, *J. Biol. Chem.* 284 (2009) 5697-5708.

[70] C. Guijas, G. Pérez-Chacón, A.M. Astudillo, J.M. Rubio, L. Gil-de-Gómez, M.A. Balboa, J. Balsinde, Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A₂-dependent synthesis of lipid droplets in human monocytes, *J. Lipid Res.* 53 (2012) 2343-2354.

[71] A. Gubern, J. Casas, M. Barceló-Torns, D. Barneda, X. de la Rosa, R. Masgrau, F. Picatoste, J. Balsinde, M.A. Balboa, E. Claro, Group IVA phospholipase A₂ is necessary for the biogenesis of lipid droplets, *J. Biol. Chem.* 283 (2008) 27369-27382.

[72] A. Gubern, M. Barceló-Torns, D. Barneda, J.M. López, R. Masgrau, F. Picatoste, C.E. Chalfant, J. Balsinde, M.A. Balboa, E. Claro, JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A₂, *J. Biol. Chem.* 284 (2009) 32359-32369.

[73] M. Divangahi, D. Desjardins, C. Nunes-Alves, H.G. Remold, S.M. Behar, Eicosanoid pathways regulate adaptive immunity to *Mycobacterium tuberculosis*, *Nat. Immunol.* 11 (2010) 751-758.

[74] S.V. Jamwal, P. Mehrotra, A. Singh, Z. Siddiqui, A. Basu, K.V. Rao, Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism, *Sci. Rep.* 6 (2016) 23089.

[75] M. Chen, M. Divangahi, H. Gan, D.S. Shin, S. Hong, D.M. Lee, C.N. Serhan, S.M. Behar, H.G. Remold, Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE₂ and LXA₄ in the induction of macrophage death, *J. Exp. Med.* 205 (2008) 2791-2801.

[76] D.A. Slatter, M. Aldrovandi, A. O'Connor, S.M. Allen, C.J. Brasher, R.C. Murphy, S. Mecklemann, S. Ravi, V. Darley-USmar, V.B. O'Donnell, Mapping the human platelet

lipidome reveals cytosolic phospholipase A₂ as a regulator of mitochondrial bioenergetics during activation, *Cell Metab.* 23 (2016) 930-944.

[77] L. Peña, C. Meana, A.M. Astudillo, G. Lordén, M. Valdearcos, H. Sato, M. Murakami, J. Balsinde, M.A. Balboa, Critical role for cytosolic group IVA phospholipase A₂ in early adipocyte differentiation and obesity, *Biochim. Biophys. Acta* 1861 (2016) 1083-1095.

[78] J. Balsinde, I.D. Bianco, E.J. Ackermann, K. Conde-Frieboes, E.A. Dennis, Inhibition of calcium-independent phospholipase A₂ prevents arachidonic acid incorporation and phospholipid remodeling in P388D₁ macrophages, *Proc. Natl. Acad. Sci. U.S.A.* 92 (1995) 8527-8531.

[79] J. Balsinde, E.A. Dennis, Function and inhibition of intracellular calcium-independent phospholipase A₂, *J. Biol. Chem.* 272 (1997) 16069-16072.

[80] J. Balsinde, M.A. Balboa, E.A. Dennis, Antisense inhibition of group VI Ca²⁺-independent phospholipase A₂ blocks phospholipid fatty acid remodeling in murine P388D₁ macrophages, *J. Biol. Chem.* 272 (1997) 29317-29321.

[81] J. Balsinde, M.A. Balboa, Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A₂ in activated cells, *Cell Signal.* 17 (2005) 1052-1062.

[82] S.B. Hooks, B.S. Cummings, Role of Ca²⁺-independent phospholipase A₂ in cell growth and signaling, *Biochem. Pharmacol.* 76 (2008) 1059-1067.

[83] X. Lei, S.E. Barbour, S. Ramanadham, Group VIA Ca²⁺-independent phospholipase A₂ (iPLA₂β) and its role in β-cell programmed cell death, *Biochimie* 92 (2010) 627-637.

[84] W.P. Wilkins, 3rd, S.E. Barbour, Group VI phospholipases A₂: homeostatic phospholipases with significant potential as targets for novel therapeutics, *Curr. Drug Targets* 9 (2008) 683-697.

[85] K. Lauber, E. Bohn, S.M. Krober, Y.J. Xiao, S.G. Blumenthal, R.K. Lindemann, P. Marini, C. Wiedig, A. Zobywalski, S. Baksh, Y. Xu, I.B. Autenrieth, K. Schulze-Osthoff, C. Belka, G. Stuhler, S. Wesselborg, Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal, *Cell* 113 (2003) 717-730.

[86] R. Pérez, M.A. Balboa, J. Balsinde, Involvement of group VIA calcium-independent phospholipase A₂ in macrophage engulfment of hydrogen peroxide-treated U937 cells, *J. Immunol.* 176 (2006) 2555-2561.

[87] S.J. Kim, D. Gershov, X. Ma, N. Brot, K.B. Elkon, I-PLA₂ activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation, *J. Exp. Med.* 196 (2002) 655-665.

[88] G. Atsumi, M. Tajima, A. Hadano, Y. Nakatani, M. Murakami, I. Kudo, Fas-induced arachidonic acid release is mediated by Ca²⁺-independent phospholipase A₂ but not cytosolic phospholipase A₂, which undergoes proteolytic inactivation, *J. Biol. Chem.* 273 (1998) 13870-13877.

[89] S. Bao, Y. Li, X. Lei, M. Wohltmann, W. Jin, A. Bohrer, C.F. Semenkovich, S. Ramanadham, I. Tabas, J. Turk, Attenuated free cholesterol loading-induced apoptosis but preserved phospholipid composition of peritoneal macrophages from mice that do not express group VIA phospholipase A₂, *J. Biol. Chem.* 282 (2007) 27100-27114.

[90] J. Balsinde, M.A. Balboa, E.A. Dennis, Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D₁ macrophage-like cells, *J. Biol. Chem.* 275 (2000) 22544-22549.

- [91] J. Pindado, J. Balsinde, M.A. Balboa, TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase A₂/cyclooxygenase-2 pathway, *J. Immunol.* 179 (2007) 4821-4828.
- [92] G. Pérez-Chacón, A.M. Astudillo, V. Ruipérez, M.A. Balboa, J. Balsinde, Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes, *J. Immunol.* 184 (2010) 1071-1078.
- [93] J. Balsinde, Roles of various phospholipases A₂ in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling, *Biochem. J.* 364 (2002) 695-702.
- [94] S.R. Panini, L. Yang, A.E. Rusinol, M.S. Sinensky, J.V. Bonventre, C.C. Leslie, Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL/oxysterol, *J. Lipid Res.* 42 (2001) 1678-1686.
- [95] J. Marshall, E. Krump, T. Lindsay, G. Downey, D.A. Ford, P.H. Zhu, P. Walker, B. Rubin, Involvement of cytosolic phospholipase A₂ and secretory phospholipase A₂ in arachidonic acid release from human neutrophils, *J. Immunol.* 164 (2000) 2084-2091.
- [96] N. Degousee, F. Ghomashchi, E. Stefanski, A. Singer, B.P. Smart, N. Borregaard, R. Reithmeier, T.F. Lindsay, C. Lichtenberger, W. Reinisch, G. Lambeau, J. Arm, J. Tischfield, M.H. Gelb, B.B. Rubin, Groups IV, V, and X phospholipases A₂s in human neutrophils - Role in eicosanoid production and gram-negative bacterial, phospholipid hydrolysis, *J. Biol. Chem.* 277 (2002) 5061-5073.
- [97] F.F. Hsu, Z.M. Ma, M. Wohltmann, A. Bohrer, W. Nowatzke, S. Ramanadham, J. Turk, Electrospray ionization/mass spectrometric analyses of human promonocytic U937 cell glycerolipids and evidence that differentiation is associated with membrane lipid composition changes that facilitate phospholipase A₂ activation, *J. Biol. Chem.* 275 (2000) 16579-16589.
- [98] M. Murakami, T. Kambe, S. Shimbara, K. Higashino, K. Hanasaki, H. Arita, M. Horiguchi, M. Arita, H. Arai, K. Inoue, I. Kudo, Different functional aspects of the group II subfamily (types IIA and V) and type X secretory phospholipase A₂s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation, *J. Biol. Chem.* 274 (1999) 31435-31444.
- [99] D.M. Nikolic, M.C. Gong, J. Turk, S.R. Post, Class A scavenger receptor-mediated macrophage adhesion requires coupling of calcium-independent phospholipase A₂ and 12/15-lipoxygenase to Rac and Cdc42 activation, *J. Biol. Chem.* 282 (2007) 33405-33411.
- [100] J. Sharma, J. Turk, J. McHowat, Endothelial cell prostaglandin I-2 and platelet-activating factor production are markedly attenuated in the calcium-independent phospholipase A₂β knockout mouse, *Biochemistry* 49 (2010) 5473-5481.
- [101] Z.W. Xie, M.C. Gong, W. Su, D.P. Xie, J. Turk, Z.H. Guo, Role of calcium-independent phospholipase A₂β in high glucose-induced activation of RhoA, Rho Kinase, and CPI-17 in cultured vascular smooth muscle cells and vascular smooth muscle hypercontractility in diabetic animals, *J. Biol. Chem.* 285 (2010) 8628-8638.
- [102] S.E. Barbour, P.T. Nguyen, M. Park, B. Emani, X. Lei, M. Kambalapalli, J.C. Shultz, D. Wijesinghe, C.E. Chalfant, S. Ramanadham, Group VIA Phospholipase A₂ (iPLA₂β) modulates Bcl-x 5'-splice site selection and suppresses anti-apoptotic Bcl-x(L) in β-cells, *J. Biol. Chem.* 290 (2015) 11021-11031.

- [103] J. McHowat, G. Gullickson, R.G. Hoover, J. Sharma, J. Turk, J. Kornbluth, Platelet-activating factor and metastasis: calcium-independent phospholipase A₂β deficiency protects against breast cancer metastasis to the lung, *Am. J. Physiol. Cell Physiol.* 300 (2011) C825-C832.
- [104] P. Rastogi, J. McHowat, Inhibition of calcium-independent phospholipase A₂ prevents inflammatory mediator production in pulmonary microvascular endothelium, *Respir. Physiol. Neurobiol.* 165 (2009) 167-174.
- [105] J. Sharma, J.R. Blase, D.F. Hoft, J.O. Marentette, J. Turk, J. McHowat, Mice with genetic deletion of Group VIA phospholipase A₂β exhibit impaired macrophage function and increased parasite load in *Trypanosoma cruzi*-induced myocarditis, *Infect. Immun.* 84 (2016) 1137-1142.
- [106] J. Sharma, C.S. Eickhoff, D.F. Hoft, J.O. Marentette, J. Turk, J. McHowat, Absence of calcium-independent phospholipase A₂β impairs platelet-activating factor production and inflammatory cell recruitment in *Trypanosoma cruzi*-infected endothelial cells, *Physiol. Rep.* 2 (2014) e00196.
- [107] H. Song, M. Wohltmann, M. Tan, J.H. Ladenson, J. Turk, Group VIA phospholipase A₂ mitigates palmitate-induced β-cell mitochondrial injury and apoptosis, *J. Biol. Chem.* 289 (2014) 14194-14210.
- [108] M.A. Balboa, J. Balsinde, Involvement of calcium-independent phospholipase A₂ in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells, *J. Biol. Chem.* 277 (2002) 40384-40389.
- [109] G.Y. Liu, S.H. Moon, C.M. Jenkins, M. Li, H.F. Sims, S. Guan, R.W. Gross, The phospholipase iPLA₂γ is a major mediator releasing oxidized aliphatic chains from cardiolipin, integrating mitochondrial bioenergetics and signaling, *J. Biol. Chem.* 292 (2017) 10672-10684.
- [110] L.A. Horrocks, A.A. Farooqui, Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function, *Prostaglandins Leukot. Essent. Fatty Acids* 70 (2004) 361-372.
- [111] H. Blanchard, A.Y. Taha, Y. Cheon, H.W. Kim, J. Turk, S.I. Rapoport, iPLA₂β knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology, *Neurochem. Res.* 39 (2014) 1522-1532.
- [112] M. Basselin, A.O. Rosa, E. Ramadan, Y. Cheon, L. Chang, M. Chen, D. Greenstein, M. Wohltmann, J. Turk, S.I. Rapoport, Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA₂β (VIA)-deficient mice, *J. Lipid Res.* 51 (2010) 3166-3173.
- [113] Y. Cheon, H.W. Kim, M. Igarashi, H.R. Modi, L. Chang, K. Ma, D. Greenstein, M. Wohltmann, J. Turk, S.I. Rapoport, A.Y. Taha, Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A₂-VIA (iPLA₂β)-knockout mice, *Biochim. Biophys. Acta* 1821 (2012) 1278-1286.
- [114] N.G. Bazan, Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection, *Curr. Opin. Clin. Nutr. Metab. Care* 10 (2007) 136-141.
- [115] N. Salem, Jr., B. Litman, H.Y. Kim, K. Gawrisch, Mechanisms of action of docosahexaenoic acid in the nervous system, *Lipids* 36 (2001) 945-959.
- [116] S.I. Rapoport, Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo, *Prostaglandins Leukot. Essent. Fatty Acids* 88 (2013) 79-85.

- [117] S.I. Rapoport, E. Ramadan, M. Basselin, Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission, *Prostaglandins Other Lipid Mediat.* 96 (2011) 109-113.
- [118] X. Zhu, J. Learoyd, S. Butt, L. Zhu, P.V. Usatyuk, V. Natarajan, N.M. Munoz, A.R. Leff, Regulation of eosinophil adhesion by lysophosphatidylcholine via a non-store-operated Ca^{2+} channel, *Am. J. Respir. Cell Mol. Biol.* 36 (2007) 585-593.
- [119] M. Murakami, S. Masuda, K. Ueda-Semmyo, E. Yoda, H. Kuwata, Y. Takanezawa, J. Aoki, H. Arai, H. Sumimoto, Y. Ishikawa, T. Ishii, Y. Nakatani, I. Kudo, Group VIB Ca^{2+} -independent phospholipase $\text{A}_{2\gamma}$ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A_2 , *J. Biol. Chem.* 280 (2005) 14028-14041.
- [120] H. Cao, K. Gerhold, J.R. Mayers, M.M. Wiest, S.M. Watkins, G.S. Hotamisligil, Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism, *Cell* 134 (2008) 933-944.
- [121] C.O. de Souza, G.K. Vannice, J.C. Rosa Neto, P.C. Calder, Is palmitoleic acid a plausible nonpharmacological strategy to prevent or control chronic metabolic and inflammatory disorders?, *Mol. Nutr. Food Res.* 62 (2018) 1700504.
- [122] A.M. Astudillo, C. Meana, C. Guijas, L. Pereira, P. Lebrero, M.A. Balboa, J. Balsinde, Occurrence and biological activity of palmitoleic acid isomers in phagocytic cells, *J. Lipid Res.* 59 (2018) 237-249.
- [123] C. Guijas, C. Meana, A.M. Astudillo, M.A. Balboa, J. Balsinde, Foamy monocytes are enriched in cis-7-hexadecenoic fatty acid (16:1n-9), a possible biomarker for early detection of cardiovascular disease, *Cell Chem. Biol.* 23 (2016) 689-699.
- [124] M.M. Yore, I. Syed, P.M. Moraes-Vieira, T. Zhang, M.A. Herman, E.A. Homan, R.T. Patel, J. Lee, S. Chen, O.D. Peroni, A.S. Dhaneshwar, A. Hammarstedt, U. Smith, T.E. McGraw, A. Saghatelian, B.B. Kahn, Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects, *Cell* 159 (2014) 318-332.
- [125] I. Syed, J. Lee, P.M. Moraes-Vieira, C.J. Donaldson, A. Sontheimer, P. Aryal, K. Wellenstein, M.J. Kolar, A.T. Nelson, D. Siegel, J. Mokrosinski, I.S. Farooqi, J.J. Zhao, M.M. Yore, O.D. Peroni, A. Saghatelian, B.B. Kahn, Palmitic acid hydroxystearic acids activate GPR40, which is involved in their beneficial effects on glucose homeostasis, *Cell Metab.* 27 (2018) 419-427.e414.
- [126] U. Smith, B.B. Kahn, Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids, *J. Intern. Med.* 280 (2016) 465-475.
- [127] P.M. Moraes-Vieira, A. Saghatelian, B.B. Kahn, GLUT4 expression in adipocytes regulates de novo lipogenesis and levels of a novel class of lipids with antidiabetic and anti-inflammatory effects, *Diabetes* 65 (2016) 1808-1815.
- [128] M.J. Kolar, S.S. Kamat, W.H. Parsons, E.A. Homan, T. Maher, O.D. Peroni, I. Syed, K. Fjeld, A. Molven, B.B. Kahn, B.F. Cravatt, A. Saghatelian, Branched fatty acid esters of hydroxy fatty acids are preferred substrates of the MODY8 protein carboxyl ester lipase, *Biochemistry* 55 (2016) 4636-4641.
- [129] J.W. Ashley, W.D. Hancock, A.J. Nelson, R.N. Bone, H.M. Tse, M. Wohltmann, J. Turk, S. Ramanadham, Polarization of macrophages toward M2 phenotype is favored by reduction in iPLA $_2\beta$ (group VIA phospholipase A_2), *J. Biol. Chem.* 291 (2016) 23268-23281.

- [130] X. Deng, J. Wang, L. Jiao, T. Utaipan, S. Tuma-Kellner, G. Schmitz, G. Liebisch, W. Stremmel, W. Chamulitrat, iPLA₂ β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling, *Biochim. Biophys. Acta* 1861 (2016) 449-461.
- [131] B. Balestrieri, J.P. Arm, Group V sPLA₂: classical and novel functions, *Biochim. Biophys. Acta* 1761 (2006) 1280-1288.
- [132] J. Balsinde, M.A. Balboa, S. Yedgar, E.A. Dennis, Group V phospholipase A₂-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D₁ macrophages, *J. Biol. Chem.* 275 (2000) 4783-4786.
- [133] M. Mitsuishi, S. Masuda, I. Kudo, M. Murakami, Human group III phospholipase A₂ suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A₂s act on distinct cellular phospholipid molecular species, *Biochim. Biophys. Acta* 1771 (2007) 1389-1396.
- [134] Y. Chen, E.A. Dennis, Expression and characterization of human group V phospholipase A₂, *Biochim. Biophys. Acta* 1394 (1998) 57-64.
- [135] M. Murakami, Y. Taketomi, Secreted phospholipase A₂ and mast cells, *Allergol. Int.* 64 (2015) 4-10.
- [136] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, K. Yamamoto, G. Lambeau, Emerging roles of secreted phospholipase A₂ enzymes: the 3rd edition, *Biochimie* 107 (2014) 105-113.
- [137] M. Murakami, K. Yamamoto, Y. Miki, R. Murase, H. Sato, Y. Taketomi, The Roles of the Secreted Phospholipase A₂ Gene Family in Immunology, *Adv. Immunol.* 132 (2016) 91-134.
- [138] B.L. Diaz, Y. Satake, E. Kikawada, B. Balestrieri, J.P. Arm, Group V secretory phospholipase A₂ amplifies the induction of cyclooxygenase 2 and delayed prostaglandin D₂ generation in mouse bone marrow culture-derived mast cells in a strain-dependent manner, *Biochim. Biophys. Acta* 1761 (2006) 1489-1497.
- [139] B. Balestrieri, V.W. Hsu, H. Gilbert, C.C. Leslie, W.K. Han, J.V. Bonventre, J.P. Arm, Group V secretory phospholipase A₂ translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis, *J. Biol. Chem.* 281 (2006) 6691-6698.
- [140] B. Balestrieri, A. Maekawa, W. Xing, M.H. Gelb, H.R. Katz, J.P. Arm, Group V secretory phospholipase A₂ modulates phagosome maturation and regulates the innate immune response against *Candida albicans*, *J. Immunol.* 182 (2009) 4891-4898.
- [141] J.M. Rubio, J.P. Rodríguez, L. Gil-de-Gómez, C. Guijas, M.A. Balboa, J. Balsinde, Group V secreted phospholipase A₂ is upregulated by IL-4 in human macrophages and mediates phagocytosis via hydrolysis of ethanolamine phospholipids, *J. Immunol.* 194 (2015) 3327-3339.
- [142] K. Yamamoto, Y. Miki, M. Sato, Y. Taketomi, Y. Nishito, C. Taya, K. Muramatsu, K. Ikeda, H. Nakanishi, R. Taguchi, N. Kambe, K. Kabashima, G. Lambeau, M.H. Gelb, M. Murakami, The role of group IIF-secreted phospholipase A₂ in epidermal homeostasis and hyperplasia, *J. Exp. Med.* 212 (2015) 1901-1919.
- [143] M. Murakami, R.S. Koduri, A. Enomoto, S. Shimbara, M. Seki, K. Yoshihara, A. Singer, E. Valentin, F. Ghomashchi, G. Lambeau, M.H. Gelb, I. Kudo, Distinct arachidonate-releasing functions of mammalian secreted phospholipase A₂s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate

- shuttling and external plasma membrane mechanisms, *J. Biol. Chem.* 276 (2001) 10083-10096.
- [144] M.A. Balboa, Y. Shirai, G. Gaietta, M.H. Ellisman, J. Balsinde, E.A. Dennis, Localization of group V phospholipase A₂ in caveolin-enriched granules in activated P388D₁ macrophage-like cells, *J. Biol. Chem.* 278 (2003) 48059-48065.
- [145] Y. Shirai, J. Balsinde, E.A. Dennis, Localization and functional interrelationships among cytosolic Group IV, secreted Group V, and Ca²⁺-independent Group VI phospholipase A₂s in P388D₁ macrophages using GFP/RFP constructs, *Biochim. Biophys. Acta* 1735 (2005) 119-129.
- [146] W. Cho, Structure, function, and regulation of group V phospholipase A₂, *Biochim. Biophys. Acta* 1488 (2000) 48-58.
- [147] M. Murakami, Y. Taketomi, C. Girard, K. Yamamoto, G. Lambeau, Emerging roles of secreted phospholipase A₂ enzymes: Lessons from transgenic and knockout mice, *Biochimie* 92 (2010) 561-582.
- [148] E. Boilard, Y. Lai, K. Larabee, B. Balestrieri, F. Ghomashchi, D. Fujioka, R. Gobeze, J.S. Coblyn, M.E. Weinblatt, E.M. Massarotti, T.S. Thornhill, M. Divangahi, H. Remold, G. Lambeau, M.H. Gelb, J.P. Arm, D.M. Lee, A novel anti-inflammatory role for secretory phospholipase A₂ in immune complex-mediated arthritis, *EMBO Mol. Med.* 2 (2010) 172-187.
- [149] S. Ohta, M. Imamura, W. Xing, J.A. Boyce, B. Balestrieri, Group V secretory phospholipase A₂ is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation, *J. Immunol.* 190 (2013) 5927-5938.
- [150] H. Sato, Y. Taketomi, A. Ushida, Y. Isogai, T. Kojima, T. Hirabayashi, Y. Miki, K. Yamamoto, Y. Nishito, T. Kobayashi, K. Ikeda, R. Taguchi, S. Hara, S. Ida, Y. Miyamoto, M. Watanabe, H. Baba, K. Miyata, Y. Oike, M.H. Gelb, M. Murakami, The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity, *Cell Metab.* 20 (2014) 119-132.
- [151] H. Sawada, M. Murakami, A. Enomoto, S. Shimbara, I. Kudo, Regulation of type V phospholipase A₂ expression and function by proinflammatory stimuli, *Eur. J. Biochem.* 263 (1999) 826-835.
- [152] H. Shinohara, M.A. Balboa, C.A. Johnson, J. Balsinde, E.A. Dennis, Regulation of delayed prostaglandin production in activated P388D₁ macrophages by group IV cytosolic and group V secretory phospholipase A₂s, *J. Biol. Chem.* 274 (1999) 12263-12268.
- [153] B.B. Boyanovsky, W. Bailey, L. Dixon, P. Shridas, N.R. Webb, Group V secretory phospholipase A₂ enhances the progression of angiotensin II-induced abdominal aortic aneurysms but confers protection against angiotensin II-induced cardiac fibrosis in apoE-deficient mice, *Am. J. Pathol.* 181 (2012) 1088-1098.
- [154] S. Loffredo, F. Borriello, R. Iannone, A.L. Ferrara, M.R. Galdiero, V. Gigantino, P. Esposito, G. Varricchi, G. Lambeau, M.A. Cassatella, F. Granata, G. Marone, Group V secreted phospholipase A₂ induces the release of proangiogenic and antiangiogenic factors by human neutrophils, *Front. Immunol.* 8 (2017) 443.
- [155] S. Bezzine, R.S. Koduri, E. Valentin, M. Murakami, I. Kudo, F. Ghomashchi, M. Sadilek, G. Lambeau, M.H. Gelb, Exogenously added human group X secreted phospholipase A₂ but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells, *J. Biol. Chem.* 275 (2000) 3179-3191.

- [156] K. Hanasaki, T. Ono, A. Saiga, Y. Morioka, M. Ikeda, K. Kawamoto, K. Higashino, K. Nakano, K. Yamada, J. Ishizaki, H. Arita, Purified group X secretory phospholipase A₂ induced prominent release of arachidonic acid from human myeloid leukemia cells, *J. Biol. Chem.* 274 (1999) 34203-34211.
- [157] D.M. Curfs, S.A. Ghesquiere, M.N. Vergouwe, I. van der Made, M.J. Gijbels, D.R. Greaves, J.S. Verbeek, M.H. Hofker, M.P. de Winther, Macrophage secretory phospholipase A₂ group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology, *J. Biol. Chem.* 283 (2008) 21640-21648.
- [158] T.S. Hallstrand, E.Y. Chi, A.G. Singer, M.H. Gelb, W.R. Henderson, Jr., Secreted phospholipase A₂ group X overexpression in asthma and bronchial hyperresponsiveness, *Am. J. Respir. Crit. Care Med.* 176 (2007) 1072-1078.
- [159] W.R. Henderson, Jr., E.Y. Chi, J.G. Bollinger, Y.T. Tien, X. Ye, L. Castelli, Y.P. Rubtsov, A.G. Singer, G.K. Chiang, T. Nevalainen, A.Y. Rudensky, M.H. Gelb, Importance of group X-secreted phospholipase A₂ in allergen-induced airway inflammation and remodeling in a mouse asthma model, *J. Exp. Med.* 204 (2007) 865-877.
- [160] A.A. Kelvin, N. Degousee, D. Banner, E. Stefanski, A.J. Leomicronn, D. Angoulvant, S.G. Paquette, S.S. Huang, A. Danesh, C.S. Robbins, H. Noyan, M. Husain, G. Lambeau, M. Gelb, D.J. Kelvin, B.B. Rubin, Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection, *Virology* 454-455 (2014) 78-92.
- [161] T.S. Hallstrand, Y. Lai, Z. Ni, R.C. Oslund, W.R. Henderson, Jr., M.H. Gelb, S.E. Wenzel, Relationship between levels of secreted phospholipase A₂ groups IIA and X in the airways and asthma severity, *Clin. Exp. Allergy* 41 (2011) 801-810.
- [162] J.D. Nolin, Y. Lai, H.L. Ogden, A.M. Manicone, R.C. Murphy, D. An, C.W. Frevert, F. Ghomashchi, G.S. Naika, M.H. Gelb, G.M. Gauvreau, A.M. Piliponsky, W.A. Altemeier, T.S. Hallstrand, Secreted PLA₂ group X orchestrates innate and adaptive immune responses to inhaled allergen, *JCI Insight* 2 (2017) e94929.
- [163] T.S. Hallstrand, Y. Lai, K.A. Hooper, R.C. Oslund, W.A. Altemeier, G. Matute-Bello, M.H. Gelb, Endogenous secreted phospholipase A₂ group X regulates cysteinyl leukotrienes synthesis by human eosinophils, *J. Allergy Clin. Immunol.* 137 (2016) 268-277.e268.
- [164] Y. Lai, R.C. Oslund, J.G. Bollinger, W.R. Henderson, Jr., L.F. Santana, W.A. Altemeier, M.H. Gelb, T.S. Hallstrand, Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A₂ group X, *J. Biol. Chem.* 285 (2010) 41491-41500.
- [165] H. Ait-Oufella, O. Herbin, C. Lahoute, C. Coatrieux, X. Loyer, J. Joffre, L. Laurans, B. Ramkhalawon, O. Blanc-Brude, S. Karabina, C.A. Girard, C. Payre, K. Yamamoto, C.J. Binder, M. Murakami, A. Tedgui, G. Lambeau, Z. Mallat, Group X secreted phospholipase A₂ limits the development of atherosclerosis in LDL receptor-null mice, *Arterioscler. Thromb. Vasc. Biol.* 33 (2013) 466-473.
- [166] X. Li, P. Shridas, K. Forrest, W. Bailey, N.R. Webb, Group X secretory phospholipase A₂ negatively regulates adipogenesis in murine models, *FASEB J.* 24 (2010) 4313-4324.
- [167] E. Jarc, A. Kump, P. Malavasic, T.O. Eichmann, R. Zimmermann, T. Petan, Lipid droplets induced by secreted phospholipase A₂ and unsaturated fatty acids protect breast cancer cells from nutrient and lipotoxic stress, *Biochim. Biophys. Acta* 1863 (2018) 247-265.
- [168] A. Pucer, V. Brglez, C. Payre, J. Pungercar, G. Lambeau, T. Petan, Group X secreted phospholipase A₂ induces lipid droplet formation and prolongs breast cancer cell survival, *Mol. Cancer* 12 (2013) 111.

- [169] T.M. McIntyre, Bioactive oxidatively truncated phospholipids in inflammation and apoptosis: formation, targets, and inactivation, *Biochim. Biophys. Acta* 1818 (2012) 2456-2464.
- [170] V.B. O'Donnell, R.C. Murphy, New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions, *Blood* 120 (2012) 1985-1992.
- [171] A. Abe, M. Hiraoka, H. Ohguro, J.J. Tesmer, J.A. Shayman, Preferential hydrolysis of truncated oxidized glycerophospholipids by lysosomal phospholipase A₂, *J. Lipid Res.* 58 (2017) 339-349.
- [172] Y. Shimanaka, N. Kono, Y. Taketomi, M. Arita, Y. Okayama, Y. Tanaka, Y. Nishito, T. Mochizuki, H. Kusuhara, A. Adibekian, B.F. Cravatt, M. Murakami, H. Arai, Omega-3 fatty acid epoxides are autocrine mediators that control the magnitude of IgE-mediated mast cell activation, *Nat. Med.* 23 (2017) 1287-1297.
- [173] Y. Miki, K. Yamamoto, Y. Taketomi, H. Sato, K. Shimo, T. Kobayashi, Y. Ishikawa, T. Ishii, H. Nakanishi, K. Ikeda, R. Taguchi, K. Kabashima, M. Arita, H. Arai, G. Lambeau, J.M. Bollinger, S. Hara, M.H. Gelb, M. Murakami, Lymphoid tissue phospholipase A₂ group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators, *J. Exp. Med.* 210 (2013) 1217-1234.
- [174] L.H. Boudreau, A.C. Duchez, N. Cloutier, D. Soulet, N. Martin, J. Bollinger, A. Pare, M. Rousseau, G.S. Naika, T. Levesque, C. Laflamme, G. Marcoux, G. Lambeau, R.W. Farndale, M. Pouliot, H. Hamzeh-Cognasse, F. Cognasse, O. Garraud, P.A. Nigrovic, H. Guderley, S. Lacroix, L. Thibault, J.W. Semple, M.H. Gelb, E. Boilard, Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A₂ to promote inflammation, *Blood* 124 (2014) 2173-2183.
- [175] N. Nagan, R.A. Zoeller, Plasmalogens: biosynthesis and functions, *Prog. Lipid Res.* 40 (2001) 199-229.
- [176] J.M. Dean, I.J. Lodhi, Structural and functional roles of ether lipids, *Protein Cell* 9 (2018) 196-206.
- [177] M.L. Blank, Z.L. Smith, E.A. Cress, F. Snyder, Molecular species of ethanolamine plasmalogens and transacylase activity in rat tissues are altered by fish oil diets, *Biochim. Biophys. Acta* 1214 (1994) 295-302.
- [178] A. Yamashita, Y. Hayashi, Y. Nemoto-Sasaki, M. Ito, S. Oka, T. Tanikawa, K. Waku, T. Sugiura, Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms, *Prog. Lipid Res.* 53 (2014) 18-81.
- [179] P.T. Ivanova, S.B. Milne, H.A. Brown, Identification of atypical ether-linked glycerophospholipid species in macrophages by mass spectrometry, *J. Lipid Res.* 51 (2010) 1581-1590.
- [180] J. Balsinde, M.A. Balboa, P.A. Insel, E.A. Dennis, Differential regulation of phospholipase D and phospholipase A₂ by protein kinase C in P388D₁ macrophages, *Biochem. J.* 321 (Pt 3) (1997) 805-809.
- [181] E. Boilard, M.E. Surette, Anti-CD3 and concanavalin A-induced human T cell proliferation is associated with an increased rate of arachidonate-phospholipid remodeling. Lack of involvement of group IV and group VI phospholipase A₂ in remodeling and increased susceptibility of proliferating T cells to CoA-independent transacyclase inhibitor-induced apoptosis, *J. Biol. Chem.* 276 (2001) 17568-17575.

- [182] F.H. Chilton, R.C. Murphy, Remodeling of arachidonate-containing phosphoglycerides within the human neutrophil, *J. Biol. Chem.* 261 (1986) 7771-7777.
- [183] A.N. Fonteh, F.H. Chilton, Rapid remodeling of arachidonate from phosphatidylcholine to phosphatidylethanolamine pools during mast cell activation, *J. Immunol.* 148 (1992) 1784-1791.
- [184] M. Hermansson, K. Hokynar, P. Somerharju, Mechanisms of glycerophospholipid homeostasis in mammalian cells, *Prog. Lipid Res.* 50 (2011) 240-257.
- [185] J.I. MacDonald, H. Sprecher, Phospholipid fatty acid remodeling in mammalian cells, *Biochim. Biophys. Acta* 1084 (1991) 105-121.
- [186] M.L. Nieto, M.E. Venable, S.A. Bauldry, D.G. Greene, M. Kennedy, D.A. Bass, R.L. Wykle, Evidence that hydrolysis of ethanolamine plasmalogens triggers synthesis of platelet-activating factor via a transacylation reaction, *J. Biol. Chem.* 266 (1991) 18699-18706.
- [187] P.P. Robichaud, K. Boulay, J.E. Munganyiki, M.E. Surette, Fatty acid remodeling in cellular glycerophospholipids following the activation of human T cells, *J. Lipid Res.* 54 (2013) 2665-2677.
- [188] O. Lespinet, B. Labedan, ORENZA: a web resource for studying ORphan ENZYme activities, *BMC Bioinformatics* 7 (2006) 436.
- [189] A.M. Astudillo, G. Pérez-Chacón, D. Balgoma, L. Gil-de-Gómez, V. Ruipérez, C. Guijas, M.A. Balboa, J. Balsinde, Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells, *Biochim. Biophys. Acta* 1811 (2011) 97-103.
- [190] A.M. Astudillo, G. Pérez-Chacón, C. Meana, D. Balgoma, A. Pol, M.A. Del Pozo, M.A. Balboa, J. Balsinde, Altered arachidonate distribution in macrophages from caveolin-1 null mice leading to reduced eicosanoid synthesis, *J. Biol. Chem.* 286 (2011) 35299-35307.
- [191] J.D. Winkler, C.M. Sung, C.F. Bennett, F.H. Chilton, Characterization of CoA-independent transacylase activity in U937 cells, *Biochim. Biophys. Acta* 1081 (1991) 339-346.
- [192] R. Pérez, X. Matabosch, A. Llebaria, M.A. Balboa, J. Balsinde, Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells, *J. Lipid Res.* 47 (2006) 484-491.
- [193] F.H. Chilton, Potential phospholipid source(s) of arachidonate used for the synthesis of leukotrienes by the human neutrophil, *Biochem. J.* 258 (1989) 327-333.
- [194] A. Yamashita, K. Tanaka, R. Kamata, T. Kumazawa, N. Suzuki, H. Koga, K. Waku, T. Sugiura, Subcellular localization and lysophospholipase/transacylation activities of human group IVC phospholipase A₂ (cPLA₂γ), *Biochim. Biophys. Acta* 1791 (2009) 1011-1022.
- [195] A. Yamashita, R. Kamata, N. Kawagishi, H. Nakanishi, H. Suzuki, T. Sugiura, K. Waku, Roles of C-terminal processing, and involvement in transacylation reaction of human group IVC phospholipase A₂ (cPLA₂γ), *J. Biochem.* 137 (2005) 557-567.
- [196] A. Yamashita, Y. Hayashi, N. Matsumoto, Y. Nemoto-Sasaki, T. Koizumi, Y. Inagaki, S. Oka, T. Tanikawa, T. Sugiura, Coenzyme-A-independent transacylation system; possible involvement of phospholipase A₂ in transacylation, *Biology* 6 (2017) 23.

- [197] L. Gil-de-Gómez, A.M. Astudillo, P. Lebrero, M.A. Balboa, J. Balsinde, Essential role for ethanolamine plasmalogen hydrolysis in bacterial lipopolysaccharide priming of macrophages for enhanced arachidonic acid release, *Front. Immunol.* 8 (2017) 1251.
- [198] P.R. Baker, J.S. Owen, A.B. Nixon, L. Thomas, R. Wooten, L.W. Daniel, J.T. O'Flaherty, R.L. Wykle, Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases, *Biochim. Biophys. Acta* 1592 (2002) 175-184.
- [199] J. Balsinde, S.E. Barbour, I.D. Bianco, E.A. Dennis, Arachidonic acid mobilization in P388D₁ macrophages is controlled by two distinct Ca²⁺-dependent phospholipase A₂ enzymes, *Proc. Natl. Acad. Sci. U.S.A.* 91 (1994) 11060-11064.
- [200] J. Balsinde, E.A. Dennis, Distinct roles in signal transduction for each of the phospholipase A₂ enzymes present in P388D₁ macrophages, *J. Biol. Chem.* 271 (1996) 6758-6765.

Figure Legends

FIGURE 1: Control of cellular fatty acid esterification to the *sn*-2 position of membrane phospholipids. This tightly controlled process involves the following events: PLA₂-mediated hydrolysis; activation of the free fatty acid by acyl-CoA synthetases (ACS); and re-incorporation into the *sn*-2 position of phospholipids by lysophospholipid:acyl-CoA acyltransferases (LPLAT). In stimulated cells the dominant reaction is the PLA₂-mediated deacylation step, which results in a dramatic increase in the levels of free fatty acid, which is now available for the synthesis of lipid mediators in the acute phase of inflammation (eicosanoids, derived from AA), and in the resolution phase of inflammation (pro-resolving lipid mediators derived from DHA, EPA or DPA).

FIGURE 2: Schematic representation of the involvement of PLA₂ enzymes in human macrophage phagocytosis. cPLA₂α translocates to the phagosomal membrane, and binding through the C2 domain assists in the formation of the phagosome itself. sPLA₂-V, presumably acting at plasma membrane, provides lysoPE molecules that may alter the structure and fluidity of a variety of microdomains, including lipid rafts, favoring oligomerization/interaction of phagocytic receptors.

FIGURE 3: cPLA₂α and iPLA₂-VIA exert their action on different phospholipid pools during cellular activation. cPLA₂α action leads to AA release and eicosanoid production. iPLA₂-VIA, by acting on phospholipids that do not contain AA but contain palmitic acid at the *sn*-1 position, may provide significant amounts of omega-3 free fatty acids for SPM synthesis, and perhaps also free 16:1 fatty acids which could be metabolized to yet undefined bioactive lipids.

FIGURE 4: Representative structures of 1-acyl, 1-alkyl, or 1-alkenyl glycerophospholipids (upper panel). 1-Alkenyl glycerophospholipids are called plasmalogens and annotated with a “p” before *sn*-1 hydrocarbon chain abbreviation. In peritoneal macrophages the fatty acid composition at *sn*-2 for the three major plasmalogens (p16:0, p18:1 and p18:0) is markedly enriched with AA (20:4) (bottom panels). A lipid extract from approximately 2 × 10⁶ mouse peritoneal macrophages was analyzed by liquid chromatography coupled to triple quadrupole mass spectrometry in MRM mode. Results are shown as means ± SE of three independent experiments with incubations in duplicate.

Figure

Figure

Figure 3

CELL ACTIVATION

Figure 4

Ether-phospholipids

1-O-Acyl-PL

1-O-Alkyl-PL

1-O-Alkenyl-PL